Inpharma Weekly

, Volume 1048, Issue 1, pp 15–16 | Cite as

Improving therapy for prostate cancer

  • Lawrence Prescott
Newsletter Article


Patients with locally advanced prostate cancer have a greater chance of survival if they receive goserelin plus radiotherapy, rather than radiotherapy alone, according to the results of a study presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) [ Philadelphia, US; May 1996 ]. The study provides the first clinical evidence of a survival benefit with this combination treatment. Also at the conference, the latest data were presented from a study comparing bicalutamide with flutamide, and from a trial investigating the role of antineoplastic chemotherapy in hormone-refractory prostate cancer.


Prostate Cancer Hydrocortisone Mitoxantrone Flutamide Advanced Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1996

Authors and Affiliations

  • Lawrence Prescott

There are no affiliations available

Personalised recommendations